CN117695387A - 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 - Google Patents

用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Download PDF

Info

Publication number
CN117695387A
CN117695387A CN202311544173.5A CN202311544173A CN117695387A CN 117695387 A CN117695387 A CN 117695387A CN 202311544173 A CN202311544173 A CN 202311544173A CN 117695387 A CN117695387 A CN 117695387A
Authority
CN
China
Prior art keywords
dose
hu5f9
doses
patients
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311544173.5A
Other languages
English (en)
Chinese (zh)
Inventor
欧文·L·唔斯曼
马克·P·超
拉温德拉·玛吉特
刘劼
延斯-皮特·福尔克默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN117695387A publication Critical patent/CN117695387A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202311544173.5A 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Pending CN117695387A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
CN201780029157.9A CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780029157.9A Division CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Publications (1)

Publication Number Publication Date
CN117695387A true CN117695387A (zh) 2024-03-15

Family

ID=60042716

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311544173.5A Pending CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN201780029157.9A Pending CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202210926503.6A Pending CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780029157.9A Pending CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202210926503.6A Pending CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Country Status (12)

Country Link
US (3) US11472878B2 (cg-RX-API-DMAC7.html)
EP (3) EP3442578B1 (cg-RX-API-DMAC7.html)
JP (3) JP7532009B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240016445A (cg-RX-API-DMAC7.html)
CN (3) CN117695387A (cg-RX-API-DMAC7.html)
AU (2) AU2017250809B2 (cg-RX-API-DMAC7.html)
CA (1) CA3019676A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909835T3 (cg-RX-API-DMAC7.html)
PL (1) PL3442578T3 (cg-RX-API-DMAC7.html)
PT (1) PT3442578T (cg-RX-API-DMAC7.html)
SI (1) SI3442578T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017181033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
EP3752190B1 (en) * 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
IL301972A (en) * 2020-10-09 2023-06-01 Sana Biotechnology Inc Methods for activating safe killing mechanisms using the CD47–SIRPα blocking factor
WO2022140659A2 (en) 2020-12-23 2022-06-30 D-10 Therapeutics, Inc. Anti-cd47 antibodies and uses thereof
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ,ベイジン Gpc3及びcd47を標的とする二重特異性抗体
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
JP6615745B2 (ja) * 2013-03-27 2019-12-04 ジェネンテック, インコーポレイテッド ベータ7インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
WO2014179132A1 (en) * 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
AU2015329696A1 (en) * 2014-10-10 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation

Also Published As

Publication number Publication date
EP4349412A3 (en) 2024-06-12
WO2017181033A1 (en) 2017-10-19
SI3442578T1 (sl) 2022-05-31
KR102505253B1 (ko) 2023-03-02
EP3442578A1 (en) 2019-02-20
US20190106491A1 (en) 2019-04-11
JP2019515899A (ja) 2019-06-13
KR20180134367A (ko) 2018-12-18
CA3019676A1 (en) 2017-10-19
AU2017250809A1 (en) 2018-10-25
JP2024059764A (ja) 2024-05-01
US11472878B2 (en) 2022-10-18
KR20240016445A (ko) 2024-02-06
US20230068235A1 (en) 2023-03-02
PL3442578T3 (pl) 2022-06-20
CN109152837A (zh) 2019-01-04
JP2022172278A (ja) 2022-11-15
EP4074339A1 (en) 2022-10-19
US20230406923A1 (en) 2023-12-21
ES2909835T3 (es) 2022-05-10
JP7532009B2 (ja) 2024-08-13
PT3442578T (pt) 2022-05-19
AU2024203396A1 (en) 2024-06-06
EP3442578A4 (en) 2019-04-10
CN115350276A (zh) 2022-11-18
US11718670B2 (en) 2023-08-08
KR20230035435A (ko) 2023-03-13
EP3442578B1 (en) 2022-02-09
AU2017250809B2 (en) 2024-02-29
EP4349412A2 (en) 2024-04-10
JP7442591B2 (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
JP7442591B2 (ja) がん処置における抗cd47薬の治療有効用量を決定及び達成する方法
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
JP7308191B2 (ja) 抗cd47剤ベースの卵巣癌療法
CN119546335A (zh) 治疗淋巴瘤的方法
HK40108467A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2023198089A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
HK40029255A (en) Anti-cd47 agent-based ovarian cancer therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108467

Country of ref document: HK